| Dr Daniel Gaitan, MD | |
|
425 N New Ballas Rd Ste 107, Saint Louis, MO 63141-6845 | |
| (314) 432-2592 | |
| (314) 432-2595 |
| Full Name | Dr Daniel Gaitan |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 38 Years |
| Location | 425 N New Ballas Rd Ste 107, Saint Louis, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598865636 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Missouri Baptist Medical Center | Town and country, MO | Hospital |
| Barnes-jewish West County Hospital | Creve coeur, MO | Hospital |
| Mercy Hospital St Louis | Saint louis, MO | Hospital |
| St Lukes Hospital | Chesterfield, MO | Hospital |
| Entity Name | West County Medical Specialists, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235342478 PECOS PAC ID: 8628105020 Enrollment ID: O20100415000838 |
News Archive
Researchers at the University of Massachusetts Medical School believe they may have found a new treatment for retinitis pigmentosa, a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young adulthood as night blindness or a loss of peripheral vision and in many cases progresses to legal blindness by age 40.
The National Neuroscience Institute and Nanyang Technological University, Singapore are collaborating to develop innovative technologies to better diagnose and treat patients with neurological conditions such as Parkinson's disease and brain injuries.
The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML).
Each year in Texas, traumatic brain injury (TBI) causes an estimated $6.8 billion worth of economic trauma in terms of deaths, emergency room visits, hospitalizations and disability, according to a study commissioned by the CORE Health Foundation. To put that dollar amount in perspective, it equals Coca-Cola's corporate profit for fiscal 2009.
Neuroscientists at MIT have developed a powerful new class of tools to reversibly shut down brain activity using different colors of light.
› Verified 2 days ago
| Entity Name | Daniel Gaitan Healthcare, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407487457 PECOS PAC ID: 4082042320 Enrollment ID: O20200319001001 |
News Archive
Researchers at the University of Massachusetts Medical School believe they may have found a new treatment for retinitis pigmentosa, a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young adulthood as night blindness or a loss of peripheral vision and in many cases progresses to legal blindness by age 40.
The National Neuroscience Institute and Nanyang Technological University, Singapore are collaborating to develop innovative technologies to better diagnose and treat patients with neurological conditions such as Parkinson's disease and brain injuries.
The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML).
Each year in Texas, traumatic brain injury (TBI) causes an estimated $6.8 billion worth of economic trauma in terms of deaths, emergency room visits, hospitalizations and disability, according to a study commissioned by the CORE Health Foundation. To put that dollar amount in perspective, it equals Coca-Cola's corporate profit for fiscal 2009.
Neuroscientists at MIT have developed a powerful new class of tools to reversibly shut down brain activity using different colors of light.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Gaitan, MD 425 N New Ballas Rd Ste 107, Saint Louis, MO 63141-6845 Ph: (314) 432-2592 | Dr Daniel Gaitan, MD 425 N New Ballas Rd Ste 107, Saint Louis, MO 63141-6845 Ph: (314) 432-2592 |
News Archive
Researchers at the University of Massachusetts Medical School believe they may have found a new treatment for retinitis pigmentosa, a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young adulthood as night blindness or a loss of peripheral vision and in many cases progresses to legal blindness by age 40.
The National Neuroscience Institute and Nanyang Technological University, Singapore are collaborating to develop innovative technologies to better diagnose and treat patients with neurological conditions such as Parkinson's disease and brain injuries.
The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML).
Each year in Texas, traumatic brain injury (TBI) causes an estimated $6.8 billion worth of economic trauma in terms of deaths, emergency room visits, hospitalizations and disability, according to a study commissioned by the CORE Health Foundation. To put that dollar amount in perspective, it equals Coca-Cola's corporate profit for fiscal 2009.
Neuroscientists at MIT have developed a powerful new class of tools to reversibly shut down brain activity using different colors of light.
› Verified 2 days ago
Dr. Isik Turker, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 4921 Parkview Pl, Div Im Cardiology, Ste 8b, Saint Louis, MO 63110 Phone: 314-362-1291 Fax: 314-362-4278 | |
Conor Mccartney, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 915 N Grand Blvd, Saint Louis, MO 63106 Phone: 314-652-4100 | |
Dr. Faris Adam Bakeer, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Barnes Jewish Hospital Plz, Div Im Hospitalist, Saint Louis, MO 63110 Phone: 314-362-1700 Fax: 314-362-9878 | |
Rehan Rais, M.D. M.B.,B.S. Internal Medicine Medicare: Medicare Enrolled Practice Location: 660 S Euclid Ave, Saint Louis, MO 63110 Phone: 314-362-5000 | |
Nathan Farkas, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Barnes Jew Hosp Plz, Saint Louis, MO 63110 Phone: 314-362-1930 | |
Dr. Nicole Foley, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110 Phone: 314-362-5000 | |
Soumojit Ghosh, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3660 Vista Ave, Saint Louis, MO 63110 Phone: 314-977-6100 Fax: 314-977-6164 |